Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences
about
The human paraoxonase gene cluster as a target in the treatment of atherosclerosisPaired measurements of paraoxonase 1 and serum amyloid A as useful disease markersParaoxonases function as unique protectors against cardiovascular diseases and diabetes: Updated experimental and clinical data.Adaptations to climate in candidate genes for common metabolic disordersTotal oxidant status, total antioxidant status, and paraoxonase and arylesterase activities during laparoscopic cholecystectomy.Association between CETP Taq1B and LIPC -514C/T polymorphisms with the serum lipid levels in a group of Tehran's population: a cross sectional study.Serum paraoxonase-1 as biomarker for improved diagnosis of fatty liver in dairy cows.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Regulation of paraoxonase 1 (PON1) in PCB 126-exposed male Sprague Dawley ratsRegulation of hepatic paraoxonase-1 expression.Hormonal and chemical regulation of paraoxonases in miceEzetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin.Association between p.Leu54Met polymorphism at the paraoxonase-1 gene and plantar fascia thickness in young subjects with type 1 diabetes.The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters.Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity.Determinants of variation in human serum paraoxonase activityIs elevated serum ceruloplasmin level associated with increased risk of coronary artery disease?Changes on the physiological lactonase activity of serum paraoxonase 1 by a diet intervention for weight loss in healthy overweight and obese women.Human paraoxonase-1 activity is related to the number of CD4+ T-cells and is restored by antiretroviral therapy in HIV-1-infected individuals.Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.Paraoxonase 1 in neurological disorders.Dominant role of paraoxonases in inactivation of the Pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-L-homoserine lactoneEthanol extract of Graptopetalum paraguayense upregulates paraoxonase 1 gene expression via an AKT/NF-κB-dependent pathway.Formaldehyde induces neurotoxicity to PC12 cells involving inhibition of paraoxonase-1 expression and activity.Paraoxonase: Its antiatherogenic role in chronic renal failure.Studies on protective effects of human paraoxonases 1 and 3 on atherosclerosis in apolipoprotein E knockout mice.Effect of preoperative atorvastatin therapy on paraoxonase activity and oxidative stress after coronary artery bypass grafting.Oxidative stress and anti-oxidative defence in patients with age-related macular degeneration.Role of paraoxonase-1 in the protection of hydrogen sulfide-donating sildenafil (ACS6) against homocysteine-induced neurotoxicity.Assessment of paraoxonase activities in patients with knee osteoarthritis.Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis.Macrophage paraoxonase 2 (PON2) expression is upregulated by unesterified cholesterol through activation of the phosphatidylinositol 3-kinase (PI3K) pathway.Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma.Ulva rigida improves carbohydrate metabolism, hyperlipidemia and oxidative stress in streptozotocin-induced diabetic rats.
P2860
Q26824356-6446BDC0-F015-492B-8304-407730F8A78BQ27006749-A1A7FD21-90A8-4A2C-88D7-5FE59A72EE7DQ30829280-A4E7C340-2796-472C-9FC5-220F48CFBF96Q33320199-A52E20FB-6A90-443D-98B2-4E67E43882FDQ33754084-C018E9C8-496F-4725-A0C9-73DF7104187AQ34149298-9A9DF756-66A1-4EC7-873A-312888C45684Q34665004-F783DF23-CF1E-4DB7-B5CC-CFAC19F5DF1CQ35567828-8144A51E-8C85-447A-96DB-67A506CFC06FQ35783249-44ADBE91-35F9-4686-8542-E594DB7420F9Q35882841-CCC54CA2-D714-42C0-91C4-323246B90EB4Q36174199-A0C9D6A0-8973-41F6-A8B5-ED0A2E769B01Q36729113-0B06D869-BACB-44B5-B461-4B88C569C646Q36807458-A2191506-8A9A-4BBB-8FC1-174D73AF4B1EQ36853503-4DE74005-AD63-4C4E-89FF-5224EDE299D5Q36966082-928D3A73-D8B3-4D38-AB02-875FB75B9989Q37098232-AA1CA42C-447D-4574-82B6-6003147935DDQ37113383-EF437F1D-81EB-4883-9ABC-18EE8C3E37ECQ37407504-0EE2C2B0-1129-4222-A05F-8CF5DA1109B3Q37639821-442187D6-BE84-49AD-A31A-02566319EAB8Q37864183-B1640818-1927-4F55-BA1D-85201B09349FQ38162323-AD35C0BD-E599-45C1-AFB0-EAA570C090DDQ39023423-F87545B1-3CF1-4E76-AE8A-5C2DC2C59542Q39379476-D3146738-5C25-4506-A13C-9C3A7772CB7AQ39603847-AF4E5C92-12C4-44CE-82E2-1A5E539DB73CQ40810367-A04FE243-8C04-4761-92B2-66406EF7510CQ43150774-3A79ADE2-14A1-48A6-BBAA-86CE2D300D0FQ43258130-A432B9C8-5EA7-446A-B02F-9443A3362330Q44584637-5E71FB70-7DB1-468C-B32E-29104FEF4C66Q46041979-86F3702C-3A81-4C2D-BFF6-B40179DDFF01Q46364037-91333D6E-7FEA-4EDB-AAC2-25367C71DE04Q46609071-6DE5B33E-6622-40E5-B874-A4F8C5354DB2Q46894826-5D1BDB08-2B92-47A3-878F-353CD08F927CQ46974046-D72E6E47-EB90-478E-B0A4-8DE2DBF0E0A7Q50525708-8FD7E7BA-36C8-46B2-B27C-6626DE00DCC6
P2860
Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences
@ast
Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences
@en
Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences
@nl
type
label
Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences
@ast
Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences
@en
Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences
@nl
prefLabel
Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences
@ast
Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences
@en
Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences
@nl
P1476
Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences
@en
P2093
Michael Aviram
Mira Rosenblat
P356
10.1097/01.MOL.0000174398.84185.0F
P407
P577
2005-08-01T00:00:00Z